|  |  |  |
| --- | --- | --- |
| **JAK is Out of the Box: Leveling Up Care for Severe Alopecia Areata Across Patient Populations**  **Release: May 15, 2025 Expiration: May 15, 2026** | | |
| **Activity Overview**  Severe alopecia areata (AA) causes a significant disease burden impacting multiple aspects of patients’ health, quality of life, and daily functioning. New treatment options, including Janus kinase (JAK) inhibitors, are becoming available, but diagnosis and management can be challenging, especially for pediatric patients and those with skin of color. Health care professionals require education on clinical presentations of AA in diverse patient populations, assessment of disease severity and disease burden, as well as topline clinical trial data regarding new and emerging JAK inhibitors in adult and adolescent patients. This online accredited CE enduring interactive monograph activity has been adapted from the live presentation of the primetime symposium at the MOPD 2025. This activity is presented as an interactive monograph format which provides content in an easily digestible format that learners can complete at their own pace. | | |
| **Target Audience** This activity is designed for an audience of US-based physicians, nurses and advanced practice providers (nurse practitioners and physician associates) of dermatology practice, including pediatric and adolescent dermatology, who treat alopecia areata. | | |
| Learning Objectives Upon completion of the educational activity, participants should be able to:   * Describe the variations in the clinical presentation of AA to accurately diagnose and assess severity of AA, including adult and adolescent patients with skin of color * Summarize the factors that contribute to the high disease burden seen in patients with AA as well as strategies to assess them in clinical practice * Critically evaluate the clinical data and expert recommendations for treatment of severe AA using JAK inhibitors | | |
| **Criteria for Success**  To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com. | | |
| **Credit provided by AKH Inc., Advancing Knowledge in Healthcare**  In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team."  **Physicians**  AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 0.75 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  **Nurses**  0.75 ANCC contact hours.  page3image2820968608**Physician Associates**  AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 5/15/2026. PAs should only claim credit commensurate with the extent of their participation.  **Commercial Support** This activity is supported by an educational grant from Pfizer, Inc. | | |
| **DISCLOSURES** | | |
| **Name** | **Relationship** | **Commercial Interest** |
| Natasha A. Mesinkovska, MD, PhD | Researcher | Abbvie, Sun Pharma, Sanofi, Regeneron |
| Speaker | Pfizer |
| Adelaide A. Hebert, MD | Advisor | Pfizer, Arcutis, Dermavant, Galderma, Almirall, Incyte, Apogee, Novartis, Sun Pharma |
| Consultant | Pfizer, Arcutis, Dermavant, Galderma, Almirall, Incyte, Apogee, Novartis |
| Researcher | all research grants paid to the medical school: |
| Dorothy Caputo, MA, BSN, RN, VP,  Healthcare CE and Operations | N/A | Nothing to disclose |
| Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
| AKH Inc Staff and Planners | N/A | Nothing to disclose |
| Tarsus dba LiVDerm Staff and Planners | N/A | Nothing to disclose |
| **All of the relevant financial relationships listed for these individuals have been mitigated.** | | |

**Disclosures**

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

**Disclosure of Unlabeled Use and Investigational Product**

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

**Disclaimer**

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.